RT Journal Article
SR Electronic
T1 Anti-SARS-CoV-2 IgM and IgG antibodies in health workers in Sergipe, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.24.20200873
DO 10.1101/2020.09.24.20200873
A1 de Melo, Mônica Santos
A1 Borges, Lysandro Pinto
A1 de Souza, Daniela Raguer Valadão
A1 Martins, Aline Fagundes
A1 de Rezende Neto, José Melquiades
A1 Ribeiro, Anderson Alves
A1 Santos, Aryanne Araujo
A1 da Invenção, Grazielly Bispo
A1 Matos, Igor Leonardo Santos
A1 Santos, Kezia Alves dos
A1 Souza, Nicolas Alessandro Alves
A1 Borges, Pâmela Chaves
A1 de Oliveira, Makson Gleydson Brito
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.24.20200873.abstract
AB Background The exponential growth of COVID-19 cases in Brazil is overloading health systems with overcrowding of hospitals and overflowing intensive care units. Increasing infection rates in health professionals can lead to the collapse of the health system and further worsen the pandemic. The aim of this study was to evaluate the seroprevalence of IgM and IgG for SARS-CoV-2 in health workers in Sergipe, Brazil.Methods The targeted tests involved health professionals working on the front line to combat COVID-19. The samples were collected in the month of June, in six hospital units in the state of Sergipe.Results 471 health professionals were tested. Of these, 28 workers (5.95%) tested positive for IgM and 64 (13.59%) tested positive for IgG. 9 workers (1.91%) tested positive for IgM and were also positive for IgG.Discussion Health workers must be monitored constantly, because if they are infected, they can spread the virus to colleagues, hospitalized patients and even family members.Conclusion Knowing the prevalence of antibodies to the virus in health workers is an important measure of viral spread control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank the Ministry of Labour and the Federal and State Public Ministries for facilitating the testing described in this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Bioethics Committee of Brazil (CAAE 31018520.0.0000.5546).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI declare that all data published in this study are available for consultation.